{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:02:43Z","timestamp":1789610563810,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Toxicity\u2010related treatment cessation (TTC) limits optimal outcomes in newly diagnosed multiple myeloma (NDMM), but its determinants and prognostic relevance remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 3095 NDMM patients were enrolled between 2018 and 2024 in the Asia\u2013Pacific and Australia\u2013New Zealand Myeloma and Related Diseases Registries. Baseline features, treatments, and outcomes were analyzed to identify predictors of TTC and assess its association with progression\u2010free survival (PFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TTC occurred in 9% of patients. Advanced age and renal function were independent predictors in multivariable logistic regression, whereas comorbidity burden was not significant after adjustment. Proteasome inhibitor exposure was associated with lower odds of TTC, while immunomodulatory drug use was not independently associated. Patients with TTC had inferior unadjusted survival (median PFS 22.1 vs. 34.4\u2009months; median OS 53.8 vs. 70.8\u2009months; both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In adjusted analyses, TTC was not associated with PFS or OS; however, in age\u2010stratified analyses, TTC remained associated with shorter PFS in patients aged &lt;\u200970\u2009years (adjusted HR 1.44,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), with no significant association observed in patients \u2265\u200970\u2009years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TTC may reflect physiologic vulnerability and retains prognostic relevance in younger patients. It may serve as a practical marker to complement frailty assessment in NDMM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70318","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:14:41Z","timestamp":1789607681000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity\u2010Related Treatment Cessation in Newly Diagnosed Multiple Myeloma\u2014Risk Factors and Survival: An Analysis From the\n                    <scp>APAC<\/scp>\n                    and\n                    <scp>ANZ<\/scp>\n                    Myeloma and Related Diseases Registry"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-4911","authenticated-orcid":false,"given":"Ji Hyun","family":"Lee","sequence":"first","affiliation":[{"name":"Dong\u2010A University College of Medicine  Busan Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5051-2413","authenticated-orcid":false,"given":"Sung\u2010Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Dong\u2010A University College of Medicine  Busan Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Sungkyunkwan University School of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-0168","authenticated-orcid":false,"given":"Elham","family":"Ashrafi","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5394","authenticated-orcid":false,"given":"Cameron","family":"Wellard","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-6000","authenticated-orcid":false,"given":"Elizabeth","family":"Moore","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"National University Hospital  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-8489","authenticated-orcid":false,"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing Chaoyang Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2129-782X","authenticated-orcid":false,"given":"Gin Gin","family":"Gan","sequence":"additional","affiliation":[{"name":"University Malaya Medical Centre  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"Phoebe Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital University of Sidney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-1198","authenticated-orcid":false,"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[{"name":"School of Medicine University of Queensland  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital Melbourne  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon","family":"Harrison","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Christchurch Hospital  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0531-7424","authenticated-orcid":false,"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"The Alfred Hospital  Melbourne Australia"},{"name":"School of Translational Medicine Alfred Health\u2013Monash University  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"5","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer Term Follow\u2010Up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)","volume":"10","author":"Durie B. G. M.","year":"2020","journal-title":"Blood Cancer Journal"},{"issue":"2","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance Until Progression in Myeloma","volume":"387","author":"Richardson P. G.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of Bortezomib, Thalidomide, and Dexamethasone (VTD) as Induction Pretransplantation Therapy in Multiple Myeloma: A Randomized Phase 3 PETHEMA\/GEM Study","volume":"120","author":"Rosinol L.","year":"2012","journal-title":"Blood"},{"issue":"3","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final Analysis of Survival Outcomes in the Phase 3 FIRST Trial of Up\u2010Front Treatment for Multiple Myeloma","volume":"131","author":"Facon T.","year":"2018","journal-title":"Blood"},{"issue":"4","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent Overall Survival Benefit and no Increased Risk of Second Malignancies With Bortezomib\u2010Melphalan\u2010Prednisone Versus Melphalan\u2010Prednisone in Patients With Previously Untreated Multiple Myeloma","volume":"31","author":"San Miguel J. F.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab and Followed by Daratumumab Maintenance or Observation in Transplant\u2010Eligible Newly Diagnosed Multiple Myeloma: Long\u2010Term Follow\u2010Up of the CASSIOPEIA Randomised Controlled Phase 3 Trial","volume":"25","author":"Moreau P.","year":"2024","journal-title":"Lancet Oncology"},{"issue":"10218","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall Survival With Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open\u2010Label, Phase 3 Trial","volume":"395","author":"Mateos M. V.","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma (MAIA): Overall Survival Results From a Randomised, Open\u2010Label, Phase 3 Trial","volume":"22","author":"Facon T.","year":"2021","journal-title":"Lancet Oncology"},{"issue":"10","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of Daratumumab to Lenalidomide, Bortezomib, and Dexamethasone for Transplantation\u2010Eligible Patients With Newly Diagnosed Multiple Myeloma (GRIFFIN): Final Analysis of an Open\u2010Label, Randomised, Phase 2 Trial","volume":"10","author":"Voorhees P. M.","year":"2023","journal-title":"Lancet Haematology"},{"issue":"4","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant\u2010Ineligible or Transplant\u2010Deferred Newly Diagnosed Multiple Myeloma: The Randomized Phase 3 CEPHEUS Trial","volume":"31","author":"Usmani S. Z.","year":"2025","journal-title":"Nature Medicine"},{"issue":"4","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld P.","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How I Treat Multiple Myeloma in Geriatric Patients","volume":"143","author":"Facon T.","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1182\/blood-2024-209640","article-title":"Initial Results From the Frailty\u2010Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI\u2010NDMM)\u2014The FRAIL\u2010M Study (AMaRC 19\u201001; ALLG MM22)","volume":"144","author":"Lim S.\u2010L.","year":"2024","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41408-024-01109-4","article-title":"Progression\u2010Free Survival as a Surrogate Endpoint in Myeloma Clinical Trials: An Evolving Paradigm","volume":"14","author":"Pawlyn C.","year":"2024","journal-title":"Blood Cancer Journal"},{"issue":"11","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal Residual Disease\u2010Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials","volume":"43","author":"Shi Q.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood-2023-184406","article-title":"A Novel Composite Endpoint of Toxicity\u2010 and Progression\u2010Free Survival After B\u2010Cell Maturation Antigen (BCMA)\u2010Directed Chimeric Antigen Receptor T\u2010Cell Therapy for Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Mohty R.","year":"2023","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12874-024-02227-0","article-title":"The Establishment of a Multiple Myeloma Clinical Registry in the Asia\u2010Pacific Region: The Asia\u2010Pacific Myeloma and Related Diseases Registry (APAC MRDR)","volume":"24","author":"Aoki N.","year":"2024","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12874-016-0250-z","article-title":"Design and Development of the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry","volume":"16","author":"Bergin K.","year":"2016","journal-title":"BMC Medical Research Methodology"},{"issue":"6","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/j.clml.2021.01.016","article-title":"The Myeloma Landscape in Australia and New Zealand: The First 8\u2009Years of the Myeloma and Related Diseases Registry (MRDR)","volume":"21","author":"Bergin K.","year":"2021","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"11","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant\u2010Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG\u2010HD7 Trial","volume":"43","author":"Mai E. K.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric Assessment Predicts Survival and Toxicities in Elderly Myeloma Patients: An International Myeloma Working Group Report","volume":"125","author":"Palumbo A.","year":"2015","journal-title":"Blood"},{"issue":"5","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A Concise Revised Myeloma Comorbidity Index as a Valid Prognostic Instrument in a Large Cohort of 801 Multiple Myeloma Patients","volume":"102","author":"Engelhardt M.","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A Simplified Frailty Scale Predicts Outcomes in Transplant\u2010Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated in the FIRST (MM\u2010020) Trial","volume":"34","author":"Facon T.","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","article-title":"A Clinical Prediction Model for Outcome and Therapy Delivery in Transplant\u2010Ineligible Patients With Myeloma (UK Myeloma Research Alliance Risk Profile): A Development and Validation Study","volume":"6","author":"Cook G.","year":"2019","journal-title":"Lancet Haematology"},{"issue":"1","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"22907","DOI":"10.1038\/s41598-021-02433-6","article-title":"Development of a New Clinical Index to Easily Assess Frailty of Elderly Patients With Multiple Myeloma in Asian Population","volume":"11","author":"Lee H. S.","year":"2021","journal-title":"Scientific Reports"},{"issue":"6","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and Organ Damage Correlate With Poor Survival in Myeloma Patients: Meta\u2010Analysis of 1435 Individual Patient Data From 4 Randomized Trials","volume":"98","author":"Bringhen S.","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/ejh.13677","article-title":"Receiving Four or Fewer Cycles of Therapy Predicts Poor Survival in Newly Diagnosed Transplant\u2010Ineligible Patients With Myeloma Who Are Treated With Bortezomib\u2010Based Induction","volume":"107","author":"Boyle S.","year":"2021","journal-title":"European Journal of Haematology"},{"issue":"1","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41408-024-01114-7","article-title":"Sustained Remission Following Finite Duration Bispecific Antibody Therapy in Patients With Relapsed\/Refractory Myeloma","volume":"14","author":"Chakraborty R.","year":"2024","journal-title":"Blood Cancer Journal"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S2152-2650(25)03406-8","article-title":"Sustained Remission After Limited\u2010Duration of Bispecific Antibody Therapy in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"25","author":"Vega G. M. D.","year":"2025","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2024-209653","article-title":"IMWG Frailty Score\u2010Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed TNE Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK\u2010MRA) Myeloma XIV FiTNEsS Trial","volume":"144","author":"Cook G.","year":"2024","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70318","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70318","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:14:51Z","timestamp":1789607691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":30,"alternative-id":["10.1111\/ejh.70318"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70318","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"2026-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ejh.70318"}}